Tempest Therapeutics Is A Clinical Stage Biotechnology Company Dedicated To Developing Innovative Small Molecule Therapeutics For Cancer Treatmentthe Company Aims To Create Novel Therapies That Target Tumor Cells And Activate Tumor Specific Immunityproviding Meaningful Benefits To Patientsfounded In 2011Tempest Is Supported By A Team Of Experienced Professionals In Oncology Drug Discovery And Development The Company Specializes In First In Class Small Molecule Product Candidateskey Products Include Amezalpattpst 1120 Which Is Currently In A Global Phase Ib Ii Trial For Advanced Or Metastatic Hepatocellular Carcinomaand Tpst 1495A Dual Antagonist Of Ep2 And Ep4 Receptorsplanned For A Phase 2 Study In Patients With Familial Adenomatous Polyposisfap Tempest Therapeutics Collaborates With Research Networks And Institutionssuch As The National Cancer Instituteto Advance Its Clinical Programsthe Company Is Listed On Nasdaq Under The Ticker Symbol Tpst And Is Based In Brisbanecalifornia
